
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is expected to see strong performance in both their immunology and oncology franchises, as well as their aesthetics business thanks to key products like Humira, Skyrizi, Botox, and Imbruvica. The recent acquisitions of Allergan, Cerevel, and ImmunoGen also add to AbbVie's diverse and growing portfolio. Upcoming catalysts, such as potential FDA approvals and new clinical data, could also drive future growth for the company. While there may be some potential risks, such as disappointing clinical data or macroeconomic challenges, AbbVie's strong pipeline and diverse offerings make it a promising investment opportunity.
Bears say
AbbVie is showing strong performance in its key drivers and has a robust pipeline with the recent acquisitions of Cerevel and ImmunoGen. However, there are still risks to the stock, such as potential challenges with commercial execution, disappointing clinical data or regulatory setbacks, and macroeconomic challenges in Aesthetics. Overall, the financial model has been moderately adjusted and the company's solid 1Q 2026 results suggest potential for continued success, but potential risks should still be considered.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares